Drug intelligence / Profile preview

LY4256984

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intrathecal

Overview

LY4256984 is a new molecular entity classified as a neuroprotectant, administered intrathecally, and is being developed by Eli Lilly and Company for the treatment of amyotrophic lateral sclerosis (ALS)[1][3][5]. It is in Phase 1 clinical trials for sporadic ALS, focusing on evaluating safety, tolerability, and pharmacokinetics. The specific mechanism of action has not been disclosed as of the latest available information[5].

Other names: LY4256984LY-4256984LY 4256984

Beyond the preview

Go deeper on LY4256984.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4256984.

Explore the full profile